Tuesday, 19 Jun 2018

You are here

Treat-to-Target in Spondyloarthropathies

Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.

Similar to how diabetes control and outcomes improved with introduction of treat to target concept in endocrinology, rheumatologists are looking to adopt similar strategies for more effective management of rheumatic disease outcomes.

In his presentation today Dr. Braun raised two important questions:

  1. what is the target in treatment of rheumatic diseases? and

  2. is T2T applicable in SpA?

While more easily defined in rheumatoid arthritis, remission is a more complicated target in SpA with axial involvement. The majority of published studies conclude that overall mortality and morbidity in SpA is linked to disease activity. Longitudinal relationship as observed between disease activity and radiographic damage over time:

Existent treatment guidelines are helpful in achieving treatment. When used in T2T approach, ASDAS showed to be effective outcome measure in axSpA comparable to DAS in RA.

 

Dr. Braun concluded that T2T can be effectively used in SpA and patients would benefit if rheumatologists follow this concept.

Add new comment

More Like This

EULAR 2018 - Podcast from Day 4

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher.

EULAR 2018 - Podcast from Day 3

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher. 

The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)

We're crazy busy at EULAR all week.  Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam.  You can find these on iTunes, SoundCloud or Stitcher.

Tune in next week for the EULAR week in review!

Changing my Mind at EULAR

Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.

EULAR 2018 - Day 2 Report

Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.